NL-OMON33424
Recruiting
Not Applicable
Response to influenza virus vaccination in patients immunocompromised due to chemotherapy - Rifluvac
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- breast cancer.
- Sponsor
- Sint Antonius Ziekenhuis
- Enrollment
- 385
- Status
- Recruiting
- Last Updated
- last year
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Patients with mamma carcinoma treated with FEC\-containing triweekly chemotherapy at moment of vaccination
- •2\.Patients with heart failure and therefore having an indication for the influenza vaccination
- •3\.Age \>\= 18 years
- •4\.Signing of informed consent
Exclusion Criteria
- •1\.Fever at time of vaccination defined as a temperature of \>\= 38\.5 °C.
- •2\.Previous/known allergic reaction to any of the components of the vaccines given, for example hypersensitivity to egg protein
- •3\.Thrombocytopenia (defined as \< 50 x 10\*9/L ) at moment of vaccination
- •4\.Treatment with prednisolone on moment of vaccination.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Evaluation of how body's defense system against infection responds to the flu vaccine in cancer patients being treated with idelalisibTo assess the immune response to an influenza vaccine in subjects with B-cell malignancies treated with idelalisibMedDRA version: 20.0 Level: PT Classification code 10065856 Term: Non-Hodgkin's lymphoma unspecified histology indolent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-003055-30-ESGilead Sciences, Inc.22
Active, not recruiting
Phase 1
Evaluation of how body's defense system against infection responds to the flu vaccine in cancer patients being treated with idelalisibTo assess the immune response to an influenza vaccine in subjects with B-cell malignancies treated with idelalisibMedDRA version: 20.0 Level: PT Classification code 10065856 Term: Non-Hodgkin's lymphoma unspecified histology indolent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-003055-30-CZGilead Sciences, Inc.22
Active, not recruiting
Phase 1
Evaluation of how body's defense system against infection responds to the flu vaccine in cancer patients being treated with idelalisibEUCTR2017-003055-30-PLGilead Sciences, Inc.22
Active, not recruiting
Phase 1
Evaluation of how body's defense system against infection responds to the flu vaccine in cancer patients being treated with idelalisibEUCTR2017-003055-30-FRGilead Sciences, Inc.22
Active, not recruiting
Phase 1
Evaluation of how body's defense system against infection responds to the flu vaccine in cancer patients being treated with idelalisibTo assess the immune response to an influenza vaccine in subjects with B-cell malignancies treated with idelalisibMedDRA version: 20.0 Level: PT Classification code 10065856 Term: Non-Hodgkin's lymphoma unspecified histology indolent System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2017-003055-30-GBGilead Sciences, Inc.22